2026 Global: Cancer Vaccine Market -Competitive Review (2032) report
Description
The 2026 Global: Cancer Vaccine Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer vaccine market by geography and historical trend. The scope of the report extends to sizing of the cancer vaccine market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BioNTech, Moderna, Gritstone Bio, ImmunityBio, Nouscom, Ultimovacs, OSE Immunotherapeutics, IO Biotech, Scancell, and Candel Therapeutics are among the ten major companies driving the cancer vaccine market through diverse platforms and advancing clinical-stage candidates. BioNTech leverages personalized and off‑the‑shelf mRNA vaccines and has multiple oncology programs including individualized neoantigen approaches and shared-antigen vaccines that have shown early clinical activity. Moderna, partnered with large oncology players and developing personalized mRNA-4157 (V940) in combination with checkpoint inhibitors, reported substantial reductions in recurrence and metastasis risk in randomized studies and remains a leading mRNA therapeutic developer. Gritstone Bio focuses on AI-curated neoantigen and shared neoantigen vaccines using its SLATE platform and has strategic partnerships to accelerate clinical development and manufacturing. ImmunityBio advances oncolytic virus–augmented vaccine strategies and combination immunotherapies, pursuing indications across solid tumors with programs designed to enhance antigen presentation and T-cell responses.
Nouscom, Nous‑209 and related engineered viral vector vaccines have induced durable neoantigen‑specific T-cell responses and increased tumor infiltration in early trials, positioning the company as a notable vector-based vaccine developer. Ultimovacs’s UV1 telomerase-targeted peptide vaccine is being developed in combination with checkpoint inhibitors and has progressed into later‑phase studies, exemplifying peptide‑based immunotherapy strategies. OSE Immunotherapeutics with its Tedopi neoepitope combination vaccine targets multiple HLA‑restricted epitopes and is focused on T‑cell vaccination approaches for difficult indications, supported by partnership and licensing activity. IO Biotech employs its T‑win® platform to modulate tumor immune environments and advance candidates that co-target immune suppressive mechanisms such as IDO/PD‑L1 to reinvigorate endogenous anti‑tumor immunity.
Scancell applies novel antigen platforms like Moditope and antibody-enhancing technologies to generate cytotoxic T‑cell responses against tumor-specific modifications and has a history of clinical-stage peptide vaccine development. Candel Therapeutics (formerly Advantagene/Candel) develops immunogenic viral‑based vaccine approaches such as CAN‑2409 that combine gene‑based vaccine strategies with immune‑stimulatory agents and oncolytic modalities to increase tumor antigen release and immune priming, reporting encouraging biomarker and relapse‑free survival signals in cohorts. Collectively these ten companies span mRNA, peptide, viral vector, oncolytic, and neoantigen‑focused modalities, frequently pursuing combination regimens with checkpoint inhibitors and personalized antigen targeting to improve durability and breadth of anti‑tumor responses—trends that underpin market forecasts and near‑term regulatory watchpoints as several late‑stage programs read out.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cancer vaccine market by geography and historical trend. The scope of the report extends to sizing of the cancer vaccine market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
BioNTech, Moderna, Gritstone Bio, ImmunityBio, Nouscom, Ultimovacs, OSE Immunotherapeutics, IO Biotech, Scancell, and Candel Therapeutics are among the ten major companies driving the cancer vaccine market through diverse platforms and advancing clinical-stage candidates. BioNTech leverages personalized and off‑the‑shelf mRNA vaccines and has multiple oncology programs including individualized neoantigen approaches and shared-antigen vaccines that have shown early clinical activity. Moderna, partnered with large oncology players and developing personalized mRNA-4157 (V940) in combination with checkpoint inhibitors, reported substantial reductions in recurrence and metastasis risk in randomized studies and remains a leading mRNA therapeutic developer. Gritstone Bio focuses on AI-curated neoantigen and shared neoantigen vaccines using its SLATE platform and has strategic partnerships to accelerate clinical development and manufacturing. ImmunityBio advances oncolytic virus–augmented vaccine strategies and combination immunotherapies, pursuing indications across solid tumors with programs designed to enhance antigen presentation and T-cell responses.
Nouscom, Nous‑209 and related engineered viral vector vaccines have induced durable neoantigen‑specific T-cell responses and increased tumor infiltration in early trials, positioning the company as a notable vector-based vaccine developer. Ultimovacs’s UV1 telomerase-targeted peptide vaccine is being developed in combination with checkpoint inhibitors and has progressed into later‑phase studies, exemplifying peptide‑based immunotherapy strategies. OSE Immunotherapeutics with its Tedopi neoepitope combination vaccine targets multiple HLA‑restricted epitopes and is focused on T‑cell vaccination approaches for difficult indications, supported by partnership and licensing activity. IO Biotech employs its T‑win® platform to modulate tumor immune environments and advance candidates that co-target immune suppressive mechanisms such as IDO/PD‑L1 to reinvigorate endogenous anti‑tumor immunity.
Scancell applies novel antigen platforms like Moditope and antibody-enhancing technologies to generate cytotoxic T‑cell responses against tumor-specific modifications and has a history of clinical-stage peptide vaccine development. Candel Therapeutics (formerly Advantagene/Candel) develops immunogenic viral‑based vaccine approaches such as CAN‑2409 that combine gene‑based vaccine strategies with immune‑stimulatory agents and oncolytic modalities to increase tumor antigen release and immune priming, reporting encouraging biomarker and relapse‑free survival signals in cohorts. Collectively these ten companies span mRNA, peptide, viral vector, oncolytic, and neoantigen‑focused modalities, frequently pursuing combination regimens with checkpoint inhibitors and personalized antigen targeting to improve durability and breadth of anti‑tumor responses—trends that underpin market forecasts and near‑term regulatory watchpoints as several late‑stage programs read out.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.